© Redbow Consulting Group 2026, All rights reserved 3 . AI as a n Orchestrated, Interoperable System within Transformed Commercial Workflows Across the spectrum of pharmaceutical organisations spoken to , so far AI has been primarily employed as an augmentation tool embedded in existing commercial workflows rather than an instrument for radical operational redesign. Common applications include content generation, medical abstract synthesis, sales call planning, objection hand ling , coaching, and automating administrative tasks. “It’s the combination of human plus AI... not AI alone — that’s the key.” AI adoption flourishes where user - centric interfaces simplify the engagement - for example, natural language querying models that shield users from complex prompt engineering. Equally important is the “human in the loop” concept, where human oversight verifies AI outputs and manages risks such as hallucinations or inaccuracies. Despite promising progress, fragmented AI tool ecosystems persist. It seemed in some cases that individuals are simply augmenting their own workflow “ in a bubble” working in a more solitary albeit more efficient way , but without any overarching redesign of the overall workflow. This feels like a missed opportunity and certainly does not maximise the transformative potential of AI. Companies deploy proprietary AI variants, Microsoft Copilot, and multi - agent systems in silos, limiting scalability and end - to - end impact. For true progress and to fulfil strategic - level impact , consolidating these tools into integrated workflows is emerging as the next priority. “We’ve all been sent on a course with the [Prompt engineer ing programme] ... it set the tone in the business that we’re going to be using this.” The business value of AI manifests when it multiplies human capability in commercial functions by specialist tools , ensuring accuracy and alignment with strategic priorities. By contrast, disjointed pilots and optional tool use risk confining AI’s impact to incremental productivity gains. If it is true that individuals are becoming increasingly dependent on the AI tools at the elbow rather than coworkers, this raises the spectre o f social isolation . External Reference The Report explores the use of AI as an augmentation tool embedded in workflows to multiply human capability . This is affirm ed in the external documents’ elaboration on agentic AI mesh architectures. Bain and the World Economic Forum describe the shift toward modular, vendor - neutral agent ecosystems governed by communication protocols such as the Model Context Protocol (MCP) and Agent - to - Agent (A2A) standards. This architectural innovation addresses the challenge of avoiding fragmented AI tool ecosystems and advocates for integration into cohesive, interoperable platforms. The emergent agent mesh concept supports scalable autonomy w hilst maintaining compliance and governance rigor — a crucial balance for Pharma, which must navigat e complex regulatory constraints. “The agentic AI mesh paradigm supports composability, distributed intelligence, vendor neutrality, and governed autonomy...” (McKinsey, 2025). These frameworks provide the foundation to transform workflow augmentation into seamless autonomous collaboration between human expertise and agentic AI. O n the issue of social isolation , A recent article in the Harvard Business Review, HBR, May - June 2026 pp 67 - 75 concludes: “ Used thoughtfully, AI can give employees more time to connect and help them find ways to do so. But as AI becomes an ever - present companion in the workday, leaders must remain clear - eyed about what’s gained — and what may be lost — for the mental health of the